13
Participants
Start Date
December 31, 2006
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
Cisplatin
"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
Docetaxel
"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
Bevacizumab
"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
Erlotinib
"* Two cycles during neoadjuvant therapy (dose escalation)~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
Radiotherapy
Radiotherapy begins as soon as possible following neoadjuvant chemotherapy, and continues for 7 weeks
Thomas Jefferson University, Philadelphia
Collaborators (1)
Genentech, Inc.
INDUSTRY
Sidney Kimmel Cancer Center at Thomas Jefferson University
OTHER